Tag: acute lymphoblastic leukemia

1. In two phase 1 studies, allogenic anti-CD19 CAR T cell (UCART19) treatment showed a manageable safety profile with relapsed or refractory B-cell acute lymphoblastic leukemia. 2. Allogenic anti-CD19 T cells demonstrated antileukemic activity in both children and adults. Evidence Rating Level: 2 (Good) Study Rundown: Although autologous anti-CD19 chimeric antigen receptor...
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to...
1. Compared to standard chemotherapy alone, the addition of the rituximab significantly improves event-free survival among adults with CD20-positive, Philadelphia chromosome (Ph)-negative, B-cell precursor Acute Lymphoblastic Leukemia (ALL). Such advantage did not, however, translate into longer overall survival. 2. The addition of rituximab did not result in a significant increase...
1. Inotuzumab ozogamaxin (IO) demonstrated significantly higher complete remission rates and median progression-free survival compared to standard chemotherapy in relapsed acute lymphoblastic leukemia (ALL). 2. Among patients with complete remission, absence of minimal residual disease and progression to stem-cell transplantation was more common with IO. Evidence Rating Level: 1 (Excellent)  Study Rundown:...
1. In a retrospective review of over 5000 children with acute lymphoblastic leukemia (ALL) who received asparaginase induction therapy, independent clinical risk factors for pancreatitis include Native American ancestry, older age, and higher cumulative doses of asparaginase. 2. Patients with specific mutations to CPA2 gene were at a significantly higher...
Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. While the prognosis associated with this disease has improved, children treated with CNS-directed chemotherapy are at risk of developing neurocognitive deficits. In...
Originally published by Harvard Health. What Is It? Acute lymphocytic leukemia (ALL) is a type of leukemia. Leukemia is a cancer of the blood or bone marrow. ALL is also known as acute lymphoblastic leukemia and acute lymphoid leukemia. ALL is a cancer of the body’s blood-making system. Blood cells are produced...
1. 90% of relapsed B-cell acute lymphoblastic leukemia (ALL) patients achieved complete remission 1 month after an infusion of engineered T-cells. 2. All patients developed the cytokine-release syndrome requiring hospitalization. Evidence Rating Level: 2 (Good) Study Rundown: ALL is the most common form of childhood cancer. Up to a quarter...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure The PARADIGM-HF trial Inhibition of neprilysin, an endopeptidase that degrades endogenous vasoactive peptides, has been shown to counteract the maladaptive vasoconstriction, sodium retention, and remodelling processes...